PANTHERx Rare Pharmacy
PANTHERx provides dispensing, clinical support, and access coordination through its RareCARE team, including PA support, appeals, and fulfillment.
pantherxrare.com
Fax: 1-877-912-0734
Phone: 1-866-347-0951
PANTHERx provides dispensing, clinical support, and access coordination through its RareCARE team, including PA support, appeals, and fulfillment.
pantherxrare.com
Fax: 1-877-912-0734
Phone: 1-866-347-0951
Interconnect provides patient support and access to financial assistance programs.
interconnectsupport.com
Fax: 1-833-636-1742
Phone: 1-844-622-4278
*Offer not valid for patients enrolled in Medicare, DoD, VA, Medicaid, or other federal or state healthcare programs. For program terms, conditions, and eligibility criteria, visit www.interconnectsupport.com
PA=Prior Authorization.
Our goal is to make prescribing LYNAVOY seamless so you can focus on patient care
“How to Start LYNAVOY” brochure will provide you with important information for prescribing LYNAVOY.
Download the “Doctor/
Success!
Thank you for signing up.
Liver Test Elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients.
Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY.
Fat-Soluble Vitamin (FSV) Deficiency: LYNAVOY may adversely affect absorption of FSV (i.e., vitamins A, D, E, and K).
The most common adverse reactions (≥5%) are diarrhea, abdominal pain, nausea, increased ALT, hemorrhage, increased AST, headache, dyspepsia, gastroesophageal reflux disease, abdominal distension, dizziness, and arthralgia.
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals 1-844-782-4278 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Please see the full Prescribing Information for LYNAVOY.
LYNAVOY (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.
Limitations of Use: Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy).